Page 9 - Automated Cell News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Automated cell. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Automated Cell Today - Breaking & Trending Today

Hemostemix Inc.: Hemostemix Announces Closing of Unit Private Placement

Hemostemix Inc.: Hemostemix Announces Closing of Unit Private Placement
Hemostemix or the
Units ) announced on April 9, 2021, for gross proceeds of $440,031.90 (the
Offering ). The Offering consisted of the issuance of an aggregate of 1,257,234 Units at a price of $0.35 per Unit. Each Unit consists of one common share in the capital of the Company (
Common Share ) and one transferable common share purchase warrant (
Warrant ), with each full Warrant entitling the holder to acquire one Common Share at a price of $0.40 per Common Share for a period of 24 months from the closing of the Offering, subject to the accelerated expiry provision described below. ....

United States , Thomas Smeenk , Regulation Service Provider , Common Shares Of The Company , World Economic Forum Technology Pioneer Award , Hemostemix Inc , Alberta Newsfile Corp , Venture Exchange , Company Common Share , Each Unit , Common Share , Common Shares , Multilateral Instrument , Minority Security Holders , Special Transactions , Ischemic Cardiomyopathy , Dilated Cardiomyopathy , Stem Cell Treatment , Regulating Stem Cells , Vitro Techniques , Stem Cells , Neural Lineage , Automated Cell , ஒன்றுபட்டது மாநிலங்களில் , ஒழுங்குமுறை சேவை வழங்குநர் , பொதுவானது பங்குகள் ஆஃப் தி நிறுவனம் ,

Hemostemix Inc.: Hemostemix Announces Warrant Repricing and Extension

Hemostemix Inc.: Hemostemix Announces Warrant Repricing and Extension
Hemostemix or the
Company ) is pleased to announce that it has, subject to TSX Venture Exchange Approval, repriced to $0.55 each, and extended the exercise period for two years, the Warrants expiring May 7, 2020 and May 28, 2020, subject to the accelerator provisions, such that the exercise period of Warrants will be reduced to thirty (30) days, if, for any ten consecutive trading days during the unexpired term of the Warrants, the weighted average closing price of the Company s listed shares achieves or exceeds the price of 120% of the applicable exercise price ($0.66). The 30-day expiry period commences on the day the Company either (i) disseminates a press release, or (ii) sends a written notice to the holders of the Warrants advising of the commencement of the exercise period. ....

United States , Thomas Smeenk , World Economic Forum Technology Pioneer Award , Hemostemix Inc , Venture Exchange Approval , Regulation Service Provider , Alberta Newsfile Corp , Venture Exchange , Insider Of The Company , Exchange Approval , Common Share , Common Shares , Original Private Placements , Multilateral Instrument , Minority Shareholders , Special Transactions , Ischemic Cardiomyopathy , Dilated Cardiomyopathy , Stem Cell Treatment , Regulating Stem Cells , Vitro Techniques , Stem Cells , Neural Lineage , Automated Cell , Looking Information , Debenture Offering ,

Hemostemix Inc.: Hemostemix Provides a Clinical Trial Update and Announces the Release and Filing of 2020 Year-end Audited Financial Statements and Management Discussion and Analysis

Calgary, Alberta (Newsfile Corp. - April 30, 2021) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce that, with the last patient follow up ....

United States , Thomas Smeenk , World Economic Forum Technology Pioneer Award , Hemostemix Inc , Regulation Service Provider , Alberta Newsfile Corp , Venture Exchange , Ischemic Cardiomyopathy , Dilated Cardiomyopathy , Stem Cell Treatment , Regulating Stem Cells , Vitro Techniques , Stem Cells , Neural Lineage , Automated Cell , Looking Information , Debenture Offering , Debenture Warrants , Common Shares , ஒன்றுபட்டது மாநிலங்களில் , உலகம் பொருளாதார மன்றம் தொழில்நுட்பம் முன்னோடி விருது , ஒழுங்குமுறை சேவை வழங்குநர் , துணிகர பரிமாற்றம் , தண்டு செல் சிகிச்சை , விட்ரோ நுட்பங்கள் , தண்டு செல்கள் ,

Hemostemix Inc.: Hemostemix Announces Completion of Phase II Clinical Trial Subject Follow Up and HMTXF Up-list

Hemostemix Inc.: Hemostemix Announces Completion of Phase II Clinical Trial Subject Follow Up and HMTXF Up-list
Hemostemix or the
Company ) is pleased to announce the completion of the Phase II Clinical Trial subject follow up, as the 65
th (final) subject has completed their last follow-up visit. With subject follow up now completed the Company is shifting its focus to completing the data analyses and reporting associated with finalizing their Phase II Clinical Trial. In addition, the Company has contracted two additional clinical research associates to assist with the completion of the source document verification process. The entry of all subjects information into the clinical trial data base and source document verification processes are ongoing and this is a crucial preliminary step in finalizing the Phase II Clinical Trial. ....

United States , Thomas Smeenk , World Economic Forum Technology Pioneer Award , Hemostemix Inc , United States District Court , Regulation Service Provider , Alberta Newsfile Corp , Venture Exchange , Health Sciences , Aspire Health Sciences , Ischemic Cardiomyopathy , Dilated Cardiomyopathy , Stem Cell Treatment , Regulating Stem Cells , Vitro Techniques , Stem Cells , Neural Lineage , Automated Cell , Looking Information , Common Shares , ஒன்றுபட்டது மாநிலங்களில் , உலகம் பொருளாதார மன்றம் தொழில்நுட்பம் முன்னோடி விருது , ஒன்றுபட்டது மாநிலங்களில் மாவட்டம் நீதிமன்றம் , ஒழுங்குமுறை சேவை வழங்குநர் , துணிகர பரிமாற்றம் , ஆரோக்கியம் அறிவியல் ,

Hemostemix Inc.: Hemostemix Announces a $2,500,000 Lead Order and its Clinical Trial and Litigation Updates

Hemostemix Inc.: Hemostemix Announces a $2,500,000 Lead Order and its Clinical Trial and Litigation Updates
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United States , Thomas Smeenk , Venture Exchange The , Alberta Securities Commission Rule , United States District Court , Common Shares Of The Company Debenture , Regulation Service Provider , Common Shares Of The Company , World Economic Forum Technology Pioneer Award , Accudata Solutions Inc , Hemostemix Inc , Polices Of The Exchange , Alberta Newsfile Corp , Venture Exchange , Company Common Share , Health Sciences , Debenture Units , Unit Offering , Each Unit , Common Share , Common Shares , Each Finder , Existing Shareholder Exemption , Existing Shareholder , Investment Dealer Exemption , Debenture Offering ,